topic

145 Preclinical development of EDIT-201, a multiplexed CRISPR-Cas12a gene edited healthy donor derived NK cells demonstrating improved persistence and resistance to the tumor microenvironment
Karrie Wong, Steven Sexton, Kelly Donahue, Lincy Prem Antony, Kevin Wasko, Jared Nasser, Glenn Leary, Amanda Pfautz, Owen Porth, William Pierce, Patricia Sousa, Sean Scott, Aaron Wilson, Kai-Hsin Chang, John Zuris, Christopher Wilson, Richard Morgan, Christopher Borges

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A87-A88; DOI: 10.1136/jitc-2020-SITC2020.0145
144 RTX-240, an allogeneic engineered red blood cell expressing 4–1BBL and IL-15TP, promotes NK cell functionality in vitro and in vivo
Anne-Sophie Dugast, Shannon McArdel, Enping Hong, Arjun Bollampalli, Maegan Hoover, Sneha Pawar, Viral Amin, Kangjian Qiao, Christopher Ta, Laurence Turka, Thomas Wickham, Sivan Elloul

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A87; DOI: 10.1136/jitc-2020-SITC2020.0144
146 Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1
Alma-Martina Cepika, Pauline P Chen, Molly Uyeda, Brandon Cieniewicz, Mansi Narula, Laura Amaya, David M Louis, Liwen Xu, Xuhuai Ji, Alice Bertaina, Rajni Agarwal-Hashmi, Mark M Davis, Everett Meyer, Rosa Bacchetta, Maria Grazia Roncarolo

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A88; DOI: 10.1136/jitc-2020-SITC2020.0146
147 CD155 blockade boosts alloreactive natural killer cell antitumor effects against osteosarcoma
Monica Cho, Madison Phillips, Longzhen Song, Amy Erbe, Christian Capitini

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A88-A89; DOI: 10.1136/jitc-2020-SITC2020.0147
148 Identification of prostate-restricted epithelial antigens for transgenic T cell adoptive therapy against prostate cancer
Diana DeLucia, Tiffany Pariva, Roland Strong, Owen Witte, John Lee

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A89; DOI: 10.1136/jitc-2020-SITC2020.0148
17 Activity sensors for noninvasive monitoring of immune response and tumor resistance during immune checkpoint blockade therapy
Quoc Mac, James Bowen, Hathaichanok Phuengkham, Anirudh Sivakumar, Congmin Xu, Fang-Yi Su, Samuel Stentz, Hyoung Sim, Adrian Harris, Tonia Li, Peng Qiu, Gabriel Kwong

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A9; DOI: 10.1136/jitc-2020-SITC2020.0017
150 GAIA-102: a new class off-the-shelf allogeneic NK-like cells that can eliminate solid tumors
Yui Harada, Yoshikazu Yonemitsu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A90-A91; DOI: 10.1136/jitc-2020-SITC2020.0150
149 GEN-011: An ATLAS^TM-guided peripheral-blood derived neoantigen-specific T cell therapy designed to improve on TIL approaches
Pranay Khare, Harshal Zope, James Perry, Victoria DeVault, Mercay Reuter, Adrienne Li, Daniel DeOliveira, Hubert Lam, Manish Jain, Jessica Flechtner, Pranay Khare

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A90; DOI: 10.1136/jitc-2020-SITC2020.0149
151 Combination NK-92MI^CD64 cell therapy approach with therapeutic antibodies to treat metastatic prostate cancer
Hallie Hintz, Bruce Walcheck, Aaron LeBeau

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A91; DOI: 10.1136/jitc-2020-SITC2020.0151
152 Adoptive T cell therapy targeting somatic p53 mutations
Peter Kim, Parisa Malekzadeh, Nolan Vale, Elizabeth Hedges, Nikolaos Zacharakis, Steven Rosenberg

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A91-A92; DOI: 10.1136/jitc-2020-SITC2020.0152

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages